New studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are revealing promising effects in managing excess mass and related second-type condition. Preclinical evidence suggest a novel mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/